Maximising profitability through commercially successful implementation of over-the-counter switches

Journal of Generic Medicines

Volumn 1, Issue 1, 2003, Pages 13-20

  Eggleston, Richard ^a   Bruce, Lindsay ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIMETIDINE; FAMOTIDINE; FLUCONAZOLE; GENERIC DRUG; KETOCONAZOLE; LOPERAMIDE; NON PRESCRIPTION DRUG; RANITIDINE;

ARTICLE; COMMON COLD; CONSUMER ATTITUDE; DRUG APPROVAL; DRUG CONTROL; DRUG COST; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; FINANCIAL MANAGEMENT; GOVERNMENT; HEALTH CARE COST; HUMAN; LEGAL ASPECT; PATENT; PHARMACY; PROFIT; VAGINA CANDIDIASIS;

EID: 33846879833     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4940013     Document Type: Article

References (5)

1. 3) 'Data exclusivity secured for innovative switches', OTC Bulletin, 16th June, pp. 1 and 18.
2. Bae, J. P. (1997) 'Drug patent expirations and the speed of generic entry', Health Services Research, Vol. 32, No. 1, pp. 87-101.
3. Medicines and Healthcare Products Regulatory Agency Website: http://www.mhra.gov.uk.
4. Reuters Business Insight (2001) 'Achieving market dominance through reformulation: A strategic insight', Datamonitor, London, UK.
5. Scott Morton, F. M. (1999) 'Entry decisions in the generic pharmaceutical industry', RAND Journal of Economics, Vol. 30, No. 3, pp. 421-440.